Abstract
Despite being a polycyclic aromatic compound, fluorenone is not classified as carcinogenic. Some of the derivatives of fluorenone and metal complexes embedded with fluorenone based ligands exhibited challenging biological activities, including anticancer activity. The current investigation hence focuses on synthesis, characterization and anticancer activities of fluorenone based ligands and their coordinate compounds of some first row transition metals. The stoichiometry of all the synthesized metal complexes is found to be 1: 2 (metal: ligand) with the general formula [M(L)2], L = singly deprotonated ligand, whereas the geometry of all the metal complexes is found to be octahedral. The synthesized ligands and their respective metal (II) complexes were found to cleave the pBR322 DNA, during gel electrophoresis studies. The inhibition of cancer cell growth has been confirmed by fluorescence imaging techniques using DAPI as staining dye. The IC50 values of ligands and their metal (II) complexes suggest that synthesized compounds are more active towards A549 (human lung adenocarcinoma) cell line when compared with the standard drug Paclitaxel. In case of MCF-7 (human breast carcinoma) cell line, compound Cu(L2)2 is found to be more active than the standard drug Paclitaxel.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
